CTI Clinical Trial and Consulting Services Announces the Formation of Italian Subsidiary and Opens Office in Milan, Italy
CTI Clinical Trial and Consulting Services (CTI) announces that it has opened an office in Milan, Italy. The office is opened through its newly created wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Italy, S.R.L.
CTI Clinical Trial and Consulting Services
(CTI) announces that it has opened an office in Milan, Italy. The office is opened through its newly created wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Italy, S.R.L.
“We believe that the market for clinical research is continuing its growth throughout Europe, and Italy is a key location,” states Patrick Earley, General Manager at CTI. “Milan has a very dynamic economy, serving as a hub for the Italian pharmaceutical and biotechnology industries, which makes it ideal for a new location. We have had ongoing relationships with many key Italian research leaders for several years, and this expansion will allow us to continue to enhance our collaborations.”
CTI has been working for nearly fifteen years in the drug development industry in North America, Europe, and South America, specializing in clinical research programs involving critically ill patient populations. The office in Italy is the seventh CTI office in Europe and the second European office to open in 2013.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
